Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$83.47 USD
+1.20 (1.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $83.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
RDY 83.47 +1.20(1.46%)
Will RDY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RDY
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Other News for RDY
Jefferies Reaffirms Their Buy Rating on ReadyTech Holdings Ltd. (RDY)
Buy Recommendation for ReadyTech Holdings Ltd. on Strong Growth and Valuation Appeal
ReadyTech Reinforces Strong Corporate Governance
ReadyTech Reports Strong Revenue and EBITDA Growth
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal